Abstract
Metformin has been used clinically for more than 60 years. As time goes by, more and more miraculous effects of metformin beyond the clinic have been discovered and discussed. In addition to the clinically approved hypoglycemic effect, it also has a positive metabolic regulation effect on the human body that cannot be ignored. Such as anti-cancer, anti-aging, brain repair, cardiovascular protection, gastrointestinal regulation, hair growth and inhibition of thyroid nodules, and other nonclinical effects. Metformin affects almost the entire body in the situation taking it over a long period, and the preventive effects of metformin in addition to treating diabetes are also beginning to be recommended in some guidelines. This review is mainly composed of four parts: the development history of metformin, the progress of clinical efficacy, the nonclinical efficacy of metformin, and the consideration and prospect of its application.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data Availability
Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.
References
Alhussain F, Alruthia Y, Al-Mandeel H, Bellahwal A, Alharbi F, Almogbel Y, Awwad O, Dala’een R, Alharbi FA (2020) Metformin improves the depression symptoms of women with polycystic ovary syndrome in a lifestyle modification progrAm. Patient Prefer Adherence 14:737–746. https://doi.org/10.2147/PPA.S244273
Araoye EF, Thomas JA, Aguh CU (2020) Hair regrowth in 2 patients with recalcitrant central centrifugal cicatricial alopecia after use of topical metformin. JAAD Case Rep 6:106–108. https://doi.org/10.1016/j.jdcr.2019.12.008
Ayoub R, Ruddy RM, Cox E, Oyefiade A, Derkach D, Laughlin S, Ades-Aron B, Shirzadi Z, Fieremans E, Macintosh BJ, De Medeiros CB, Skocic J, Bouffet E, Miller FD, Morshead CM, Mabbott DJ (2020) Assessment of cognitive and neural recovery in survivors of pediatric brain tumors in a pilot clinical trial using metformin. Nat Med 26:1285–1294. https://doi.org/10.1038/s41591-020-0985-2
Ba W, Xu Y, Yin G, Yang J, Wang R, Chi S, Wang Y, Li C (2019) Metformin inhibits pro-inflammatory responses via targeting nuclear factor-kappaB in HaCaT cells. Cell Biochem Funct 37:4–10. https://doi.org/10.1002/cbf.3367
Bailey CJ (2017) Metformin: historical overview. Diabetologia 60:1566–1576. https://doi.org/10.1007/s00125-017-4318-z
Bakris GL, Molitch ME (2016) Should restrictions be relaxed for metformin use in chronic kidney disease? Yes, they should be relaxed! what’s the fuss? Diabetes Care 39:1287–1291. https://doi.org/10.2337/dc15-2534
Balsells M, Garcia-Patterson A, Sola I, Roque M, Gich I, Corcoy R (2015) Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis. BMJ 350:h102. https://doi.org/10.1136/bmj.h102
Banerjee J, Bruckbauer A, Zemel MB (2016) Activation of the AMPK/Sirt1 pathway by a leucine-metformin combination increases insulin sensitivity in skeletal muscle, and stimulates glucose and lipid metabolism and increases life span in Caenorhabditis elegans. Metabolism 65:1679–1691. https://doi.org/10.1016/j.metabol.2016.06.011
Bashir M, Aboulfotouh M, Dabbous Z, Mokhtar M, Siddique M, Wahba R, Ibrahim A, Brich SA, Konje JC, Abou-Samra AB (2020) Metformin-treated-GDM has lower risk of macrosomia compared to diet-treated GDM- a retrospective cohort study. J Matern Fetal Neonatal Med 33:2366–2371. https://doi.org/10.1080/14767058.2018.1550480
Bayraktar S, Hernadez-Aya LF, Lei X, Meric-Bernstam F, Litton JK, Hsu L, Hortobagyi GN, Gonzalez-Angulo AM (2012) Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer 118:1202–1211. https://doi.org/10.1002/cncr.26439
Beisswenger PJ, Howell SK, Touchette AD, Lal S, Szwergold BS (1999) Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes 48:198–202. https://doi.org/10.2337/diabetes.48.1.198
Bodmer M, Becker C, Meier C, Jick SS, Meier CR (2012) Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis. Am J Gastroenterol 107:620–626. https://doi.org/10.1038/ajg.2011.483
Borbely Z (2016) Chronic kidney diseases, metformin and lactic acidosis. Vnitr Lek 62:299–303
Bybel B, Greenberg ID, Paterson J, Ducharme J, Leslie WD (2011) Increased F-18 FDG intestinal uptake in diabetic patients on metformin: a matched case-control analysis. Clin Nucl Med 36:452–456. https://doi.org/10.1097/RLU.0b013e318217399e
Calco GN, Proskocil BJ, Jacoby DB, Fryer AD, Nie Z (2021) Metformin prevents airway hyperreactivity in rats with dietary obesity. Am J Physiol Lung Cell Mol Physiol 321:L1105–L1118. https://doi.org/10.1152/ajplung.00202.2021
Chaiteerakij R, Yang JD, Harmsen WS, Slettedahl SW, Mettler TA, Fredericksen ZS, Kim WR, Gores GJ, Roberts RO, Olson JE, Therneau TM, Roberts LR (2013) Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk. Hepatology 57:648–655. https://doi.org/10.1002/hep.26092
Chen K, Qian W, Jiang Z, Cheng L, Li J, Sun L, Zhou C, Gao L, Lei M, Yan B, Cao J, Duan W, Ma Q (2017) Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer. Mol Cancer 16:131. https://doi.org/10.1186/s12943-017-0701-0
Chen L, Zhang Y, Yin L, Cai B, Huang P, Li X, Liang G (2021a) Fibroblast growth factor receptor fusions in cancer: opportunities and challenges. J Exp Clin Cancer Res 40:345. https://doi.org/10.1186/s13046-021-02156-6
Chen YH, Wang PH, Chen PN, Yang SF, Hsiao YH (2021b) Molecular and cellular mechanisms of metformin in cervical cancer. Cancers (Basel). https://doi.org/10.3390/cancers13112545
Chen YH, Wu JX, Yang SF, Chen ML, Chen TH, Hsiao YH (2021c) Metformin potentiates the anticancer effect of everolimus on cervical cancer in vitro and in vivo. Cancers (Basel). https://doi.org/10.3390/cancers13184612
Coll AP, Chen M, Taskar P, Rimmington D, Patel S, Tadross JA, Cimino I, Yang M, Welsh P, Virtue S, Goldspink DA, Miedzybrodzka EL, Konopka AR, Esponda RR, Huang JT, Tung YCL, Rodriguez-Cuenca S, Tomaz RA, Harding HP, Melvin A, Yeo GSH, Preiss D, Vidal-Puig A, Vallier L, Nair KS, Wareham NJ, Ron D, Gribble FM, Reimann F, Sattar N, Savage DB, Allan BB, O’rahilly S (2020) GDF15 mediates the effects of metformin on body weight and energy balance. Nature 578:444–448. https://doi.org/10.1038/s41586-019-1911-y
Coyle C, Cafferty FH, Vale C, Langley RE (2016) Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann Oncol 27:2184–2195. https://doi.org/10.1093/annonc/mdw410
Crist M, Yaniv B, Palackdharry S, Lehn MA, Medvedovic M, Stone T, Gulati S, Karivedu V, Borchers M, Fuhrman B, Crago A, Curry J, Martinez-Outschoorn U, Takiar V, Wise-Draper TM (2022) Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition. J Immunother Cancer. https://doi.org/10.1136/jitc-2022-005632
Crowley MJ, Diamantidis CJ, McDuffie JR, Cameron CB, Stanifer JW, Mock CK, Wang X, Tang S, Nagi A, Kosinski AS, Williams JW Jr (2017) Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: a systematic review. Ann Intern Med 166:191–200. https://doi.org/10.7326/M16-1901
De La Cuesta-Zuluaga J, Mueller NT, Corrales-Agudelo V, Velasquez-Mejia EP, Carmona JA, Abad JM, Escobar JS (2017) Metformin Is associated with higher relative abundance of mucin-degrading Akkermansia muciniphila and several short-chain fatty acid-producing microbiota in the gut. Diabetes Care 40:54–62. https://doi.org/10.2337/dc16-1324
Di Matteo S, Nevi L, Overi D, Landolina N, Faccioli J, Giulitti F, Napoletano C, Oddi A, Marziani AM, Costantini D, De Rose AM, Melandro F, Bragazzi MC, Grazi GL, Berloco PB, Giuliante F, Donato G, Moretta L, Carpino G, Cardinale V, Gaudio E, Alvaro D (2021) Metformin exerts anti-cancerogenic effects and reverses epithelial-to-mesenchymal transition trait in primary human intrahepatic cholangiocarcinoma cells. Sci Rep 11:2557. https://doi.org/10.1038/s41598-021-81172-0
Ding Y, Zhou Y, Ling P, Feng X, Luo S, Zheng X, Little PJ, Xu S, Weng J (2021) Metformin in cardiovascular diabetology: a focused review of its impact on endothelial function. Theranostics 11:9376–9396. https://doi.org/10.7150/thno.64706
Dong S, Ruiz-Calderon B, Rathinam R, Eastlack S, Maziveyi M, Alahari SK (2020) Knockout model reveals the role of Nischarin in mammary gland development, breast tumorigenesis and response to metformin treatment. Int J Cancer 146:2576–2587. https://doi.org/10.1002/ijc.32690
Duan Y, Zhang R, Zhang M, Sun L, Dong S, Wang G, Zhang J, Zhao Z (2013) Metformin inhibits food intake and neuropeptide Y gene expression in the hypothalamus. Neural Regen Res 8:2379–2388. https://doi.org/10.3969/j.issn.1673-5374.2013.25.009
Elgendy M, Ciro M, Hosseini A, Weiszmann J, Mazzarella L, Ferrari E, Cazzoli R, Curigliano G, Decensi A, Bonanni B, Budillon A, Pelicci PG, Janssens V, Ogris M, Baccarini M, Lanfrancone L, Weckwerth W, Foiani M, Minucci S (2019) Combination of hypoglycemia and metformin impairs tumor metabolic plasticity and growth by modulating the PP2A-GSK3beta-MCL-1 axis. Cancer Cell 35:798–815. https://doi.org/10.1016/j.ccell.2019.03.007
Eppinga RN, Kofink D, Dullaart RP, Dalmeijer GW, Lipsic E, Van Veldhuisen DJ, Van Der Horst IC, Asselbergs FW, Van Der Harst P (2017) Effect of metformin on metabolites and relation with myocardial infarct size and left ventricular ejection fraction after myocardial infarction. Circ Cardiovasc Genet. https://doi.org/10.1161/CIRCGENETICS.116.001564
Fahy GM, Brooke RT, Watson JP, Good Z, Vasanawala SS, Maecker H, Leipold MD, Lin DT, Kobor MS, Horvath S (2019) Reversal of epigenetic aging and immunosenescent trends in humans. Aging Cell 18:e13028
Fan J, Li D, Chen HS, Huang JG, Xu JF, Zhu WW, Chen JG, Wang F (2019) Metformin produces anxiolytic-like effects in rats by facilitating GABAA receptor trafficking to membrane. Br J Pharmacol 176:297–316. https://doi.org/10.1111/bph.14519
Feng X, Chen W, Ni X, Little PJ, Xu S, Tang L, Weng J (2021) Metformin macrophage dysfunction and atherosclerosis. Front Immunol 12:682853. https://doi.org/10.3389/fimmu.2021.682853
Fidan E, Onder Ersoz H, Yilmaz M, Yilmaz H, Kocak M, Karahan C, Erem C (2011) The effects of rosiglitazone and metformin on inflammation and endothelial dysfunction in patients with type 2 diabetes mellitus. Acta Diabetol 48:297–302. https://doi.org/10.1007/s00592-011-0276-y
Flory J, Lipska K (2019) Metformin in 2019. JAMA 321:1926–1927. https://doi.org/10.1001/jama.2019.3805
Foretz M, Guigas B, Viollet B (2019) Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nat Rev Endocrinol 15:569–589. https://doi.org/10.1038/s41574-019-0242-2
Glossmann HH, Lutz OMD (2019) Metformin and aging: a review. Gerontology 65:581–590. https://doi.org/10.1159/000502257
Gollavilli PN, Kanugula AK, Koyyada R, Karnewar S, Neeli PK, Kotamraju S (2015) AMPK inhibits MTDH expression via GSK3beta and SIRT1 activation: potential role in triple negative breast cancer cell proliferation. FEBS J 282:3971–3985. https://doi.org/10.1111/febs.13391
Goodwin PJ, Chen BE, Gelmon KA, Whelan TJ, Ennis M, Lemieux J, Ligibel JA, Hershman DL, Mayer IA, Hobday TJ, Bliss JM, Rastogi P, Rabaglio-Poretti M, Mukherjee SD, Mackey JR, Abramson VG, Oja C, Wesolowski R, Thompson AM, Rea DW, Stos PM, Shepherd LE, Stambolic V, Parulekar WR (2022) Effect of metformin vs placebo on invasive disease-free survival in patients with breast cancer: the MA.32 randomized clinical trial. JAMA 327:1963–1973. https://doi.org/10.1001/jama.2022.6147
Gosmanov AR, Gemoets DE, Kaminsky LS, Kovesdy CP, Gosmanova EO (2021) Efficacy of metformin monotherapy in US veterans with type 2 diabetes and preexisting chronic kidney disease stage 3. Diabetes Obes Metab 23:1879–1885. https://doi.org/10.1111/dom.14414
Griffin SJ, Leaver JK, Irving GJ (2017) Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia 60:1620–1629. https://doi.org/10.1007/s00125-017-4337-9
Gu X, Han YY, Yang CY, Ji HM, Lan YJ, Bi YQ, Zheng C, Qu J, Cheng MH, Gao J (2021) Activated AMPK by metformin protects against fibroblast proliferation during pulmonary fibrosis by suppressing FOXM1. Pharmacol Res 173:105844. https://doi.org/10.1016/j.phrs.2021.105844
Guo Y, Shi J, Wang Q, Hong L, Chen M, Liu S, Yuan X, Jiang S (2021) Metformin alleviates allergic airway inflammation and increases Treg cells in obese asthma. J Cell Mol Med 25:2279–2284. https://doi.org/10.1111/jcmm.16269
Gupta G, Pinto DJA, T, Chellappan D K, Mishra A, Malipeddi H, and Dua K, (2018) A clinical update on metformin and lung cancer in diabetic patients. Panminerva Med 60:70–75. https://doi.org/10.23736/S0031-0808.18.03394-3
Han Y, Xie H, Liu Y, Gao P, Yang X, Shen Z (2019) Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. Cardiovasc Diabetol 18:96. https://doi.org/10.1186/s12933-019-0900-7
Hausmann VL, Schubotz R (1975) Proinsulin and insulin secretion in obese females before and after administration of metformin. Arzneimittelforschung 25:668–675
He X, Wu D, Hu C, Xu T, Liu Y, Liu C, Xu B, Tang W (2019) Role of metformin in the treatment of patients with thyroid nodules and insulin resistance: a systematic review and meta-analysis. Thyroid 29:359–367. https://doi.org/10.1089/thy.2017.0707
He S, Qian X, Chen Y, Shen X, Zhang B, Chen X, Xu X, Li G (2021) Risk of death and heart failure among patients with Type 2 diabetes treated by metformin and nonmetformin monotherapy: a real-world study. j Diabetes Res 2021:5534387. https://doi.org/10.1155/2021/5534387
Hwang IK, Kim IY, Joo EJ, Shin JH, Choi JW, Won MH, Yoon YS, Seong JK (2010) Metformin normalizes type 2 diabetes-induced decrease in cell proliferation and neuroblast differentiation in the rat dentate gyrus. Neurochem Res 35:645–650. https://doi.org/10.1007/s11064-009-0115-5
Jia W, Bai T, Zeng J, Niu Z, Fan D, Xu X, Luo M, Wang P, Zou Q, Dai X (2021) Combined administration of metformin and atorvastatin attenuates diabetic cardiomyopathy by inhibiting inflammation, apoptosis, and oxidative stress in Type 2 diabetic mice. Front Cell Dev Biol 9:634900. https://doi.org/10.3389/fcell.2021.634900
Kaewpitoon SJ, Loyd RA, Rujirakul R, Panpimanmas S, Matrakool L, Tongtawee T, Kootanavanichpong N, Kompor P, Chavengkun W, Kujapun J, Norkaew J, Ponphimai S, Padchasuwan N, Pholsripradit P, Eksanti T, Phatisena T, Kaewpitoon N (2015) Benefits of metformin use for cholangiocarcinoma. Asian Pac J Cancer Prev 16:8079–8083. https://doi.org/10.7314/apjcp.2015.16.18.8079
Kaisar MA, Villalba H, Prasad S, Liles T, Sifat AE, Sajja RK, Abbruscato TJ, Cucullo L (2017) Offsetting the impact of smoking and e-cigarette vaping on the cerebrovascular system and stroke injury: is Metformin a viable countermeasure? Redox Biol 13:353–362. https://doi.org/10.1016/j.redox.2017.06.006
Kalmykova ZA, Kononenko IV, Mayorov AY (2019a) Diabetes mellitus and chronic liver diseases. Literature review (part 2): treatment features. Ter Arkh 91:115–121. https://doi.org/10.26442/00403660.2019.12.000166
Kalmykova ZA, Kononenko IV, Mayorov AY (2019b) Diabetes mellitus and chronic liver diseases. Part 1: general mechanisms of etiology and pathogenesis. Ter Arkh 91:106–111. https://doi.org/10.26442/00403660.2019.10.000165
Khan MS, Solomon N, DeVore AD, Abhinav Sharma G, Felker M, Hernandez AF, Heidenreich PA, Matsouaka RA, Green JB, Butler J, Yancy CW, Peterson PN, Fonarow GC, Greene SJ (2022) Clinical outcomes with metformin and sulfonylurea therapies among patients with heart failure and diabetes. JACC Heart Fail 10:198–210
Kheirollahi V, Wasnick RM, Biasin V, Vazquez-Armendariz AI, Chu X, Moiseenko A, Weiss A, Wilhelm J, Zhang JS, Kwapiszewska G, Herold S, Schermuly RT, Mari B, Li X, Seeger W, Gunther A, Bellusci S, El Agha E (2019) Metformin induces lipogenic differentiation in myofibroblasts to reverse lung fibrosis. Nat Commun 10:2987. https://doi.org/10.1038/s41467-019-10839-0
Kim HJ, Park EY, Oh MJ, Park SS, Shin KH, Choi SH, Chun BG, Kim DH (2013) Central administration of metformin into the third ventricle of C57BL/6 mice decreases meal size and number and activates hypothalamic S6 kinase. Am J Physiol Regul Integr Comp Physiol 305:R499-505. https://doi.org/10.1152/ajpregu.00099.2013
Kim K, Yang WH, Jung YS, Cha JH (2020) A new aspect of an old friend: the beneficial effect of metformin on anti-tumor immunity. BMB Rep 53(10):512
Ko E, Baek S, Kim J, Park D, Lee Y (2020) Antitumor activity of combination therapy with metformin and trametinib in non-small cell lung cancer cells. Dev Reprod 24:113–123. https://doi.org/10.12717/DR.2020.24.2.113
Krysiak R, Szkrobka W, Okopien B (2015) The effect of metformin on the hypothalamic-pituitary-thyroid axis in patients with type 2 diabetes and subclinical hyperthyroidism. Exp Clin Endocrinol Diabetes 123:205–208. https://doi.org/10.1055/s-0034-1398621
Kuan YC, Huang KW, Lin CL, Hu CJ, Kao CH (2017) Effects of metformin exposure on neurodegenerative diseases in elderly patients with type 2 diabetes mellitus. Prog Neuropsychopharmacol Biol Psychiatry 79:77–83. https://doi.org/10.1016/j.pnpbp.2017.06.002
Kumari S, Bubak M, Schoenberg HM, Davidyan A, Elliehausen CJ, Kuhn KG, Vanwagoner TM, Karaman R, Scofield RH, Miller BF, Konopka AR (2021) Antecedent metabolic health and metformin (ANTHEM) aging study: rationale and study design for a randomized controlled trial. J Gerontol A Biol Sci Med Sci. https://doi.org/10.1093/gerona/glab358
Kwon S, Kim YC, Park JY, Lee J, An JN, Kim CT, Oh S, Park S, Kim DK, Oh YK, Kim YS (2020) The long-term effects of metformin on patients with type 2 diabetic Kidney disease. Diabetes Care 43:948–955
Lee A, Morley JE (1998) Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res 6:47–53. https://doi.org/10.1002/j.1550-8528.1998.tb00314.x
Lee J, Yesilkanal AE, Wynne JP, Frankenberger C, Liu J, Yan J, Elbaz M, Rabe DC, Rustandy FD, Tiwari P, Grossman EA, Hart PC, Kang C, Sanderson SM, Andrade J, Nomura DK, Bonini MG, Locasale JW, Rosner MR (2019) Effective breast cancer combination therapy targeting BACH1 and mitochondrial metabolism. Nature 568:254–258. https://doi.org/10.1038/s41586-019-1005-x
Li SN, Wang X, Zeng QT, Feng YB, Cheng X, Mao XB, Wang TH, Deng HP (2009) Metformin inhibits nuclear factor kappaB activation and decreases serum high-sensitivity C-reactive protein level in experimental atherogenesis of rabbits. Heart Vessels 24:446–453. https://doi.org/10.1007/s00380-008-1137-7
Li CJ, Tzeng YT, Chiu YH, Lin HY, Hou MF, Chu PY (2021) Pathogenesis and potential therapeutic targets for triple-negative breast cancer. Cancers (Basel). https://doi.org/10.3390/cancers13122978
Li X, Cai Y, Luo J, Ding J, Yao G, Xiao X, Tang Y, Liang Z (2021b) Metformin attenuates hypothalamic inflammation via downregulation of RIPK1-independent microglial necroptosis in diet-induced obese mice. Cell Death Discov 7:338. https://doi.org/10.1038/s41420-021-00732-5
Lin Y, Wang K, Ma C, Wang X, Gong Z, Zhang R, Zang D, Cheng Y (2018a) Corrigendum: evaluation of metformin on cognitive improvement in patients with non-dementia vascular cognitive impairment and abnormal glucose metabolism. Front Aging Neurosci 10:322. https://doi.org/10.3389/fnagi.2018.00322
Lin Y, Wang K, Ma C, Wang X, Gong Z, Zhang R, Zang D, Cheng Y (2018b) Evaluation of metformin on cognitive improvement in patients with non-dementia vascular cognitive impairment and abnormal glucose metabolism. Front Aging Neurosci 10:227. https://doi.org/10.3389/fnagi.2018.00227
Ling S, Xie H, Yang F, Shan Q, Dai H, Zhuo J, Wei X, Song P, Zhou L, Xu X, Zheng S (2017) Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1. J Hematol Oncol 10:59. https://doi.org/10.1186/s13045-017-0424-0
Liu YS, Chen CN, Chen ZG, Peng Y, Lin XP, Xu LL (2020) Vascular and metabolic effects of metformin added to insulin therapy in patients with type 1 diabetes: a systematic review and meta-analysis. Diabetes Metab Res Rev 36:e3334. https://doi.org/10.1002/dmrr.3334
Liu S, Polsdofer EV, Zhou L, Ruan S, Lyu H, Hou D, Liu H, Thor AD, He Z, Liu B (2021) Upregulation of endogenous TRAIL-elicited apoptosis is essential for metformin-mediated antitumor activity against TNBC and NSCLC. Mol Ther Oncolytics 21:303–314. https://doi.org/10.1016/j.omto.2021.04.012
Løvvik TS, Carlsen SM, Salvesen Ø, Steffensen B, Bixo M, Gómez-Real F, Lønnebotn M, Hestvold KV, Zabielska R, Hirschberg AL, Trouva A (2019) Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 7:256–266
Lu H, Han X, Ren J, Ren K, Li Z, Zhang Q (2021a) Metformin attenuates synergic effect of diabetes mellitus and Helicobacter pylori infection on gastric cancer cells proliferation by suppressing PTEN expression. J Cell Mol Med 25:4534–4542. https://doi.org/10.1111/jcmm.15967
Lu T, Li M, Zhao M, Huang Y, Bi G, Liang J, Chen Z, Zheng Y, Xi J, Lin Z, Zhan C, Jiang W, Wang Q, Tan L (2021b) Metformin inhibits human non-small cell lung cancer by regulating AMPK-CEBPB-PDL1 signaling pathway. Cancer Immunol Immunother. https://doi.org/10.1007/s00262-021-03116-x
Lustig RH, Schmidt LA, Brindis CD (2012) Public health: the toxic truth about sugar. Nature 482:27–29. https://doi.org/10.1038/482027a
Ma WQ, Sun XJ, Zhu Y, Liu NF (2021) Metformin attenuates hyperlipidaemia-associated vascular calcification through anti-ferroptotic effects. Free Radic Biol Med 165:229–242. https://doi.org/10.1016/j.freeradbiomed.2021.01.033
Ma T, Tian X, Zhang B, Li M, Wang Y, Yang C, Wu J, Wei X, Qu Q, Yu Y, Long S, Feng JW, Li C, Zhang C, Xie C, Wu Y, Xu Z, Chen J, Yu Y, Huang X, He Y, Yao L, Zhang L, Zhu M, Wang W, Wang ZC, Zhang M, Bao Y, Jia W, Lin SY, Ye Z, Piao HL, Deng X, Zhang CS, Lin SC (2022) Low-dose metformin targets the lysosomal AMPK pathway through PEN2. Nature 603:159–165. https://doi.org/10.1038/s41586-022-04431-8
Mandwie M, Karunia J, Niaz A, Keay KA, Musumeci G, Rennie C, Mcgrath K, Al-Badri G, Castorina A (2021) Metformin treatment attenuates brain inflammation and rescues PACAP/VIP neuropeptide alterations in mice fed a high-fat diet. Int J Mol Sci. https://doi.org/10.3390/ijms222413660
Masarwa R, Brunetti VC, Aloe S, Henderson M, Platt RW, Filion KB (2021) Efficacy and safety of metformin for obesity: a systematic review. Pediatrics. https://doi.org/10.1542/peds.2020-1610
Misirkic Marjanovic MS, Vucicevic LM, Despotovic AR, Stamenkovic MM, Janjetovic KD (2021) Dual anticancer role of metformin: an old drug regulating AMPK dependent/independent pathways in metabolic, oncogenic/tumorsuppresing and immunity context. Am J Cancer Res 11:5625–5643
Mohan M, Al-Talabany S, Mckinnie A, Mordi IR, Singh JSS, Gandy SJ, Baig F, Hussain MS, Bhalraam U, Khan F, Choy AM, Matthew S, Houston JG, Struthers AD, George J, Lang CC (2019) A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial. Eur Heart J 40:3409–3417. https://doi.org/10.1093/eurheartj/ehz203
Moses RG (2010) Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update. Diabetes Metab Syndr Obes 3:145–154. https://doi.org/10.2147/dmsott.s6621
Mossmann D, Park S, Hall MN (2018) mTOR signalling and cellular metabolism are mutual determinants in cancer. Nat Rev Cancer 18:744–757. https://doi.org/10.1038/s41568-018-0074-8
Munoz LE, Huang L, Bommireddy R, Sharma R, Monterroza L, Guin RN, Samaranayake SG, Pack CD, Ramachandiran S, Reddy SJC, Shanmugam M, Selvaraj P (2021) Metformin reduces PD-L1 on tumor cells and enhances the anti-tumor immune response generated by vaccine immunotherapy. J Immunother Cancer. https://doi.org/10.1136/jitc-2021-002614
Murff HJ, Roumie CL, Greevy RA, Hackstadt AJ, Mcgowan LED, Hung AM, Grijalva CG, Griffin MR (2018) Metformin use and incidence cancer risk: evidence for a selective protective effect against liver cancer. Cancer Causes Control 29:823–832. https://doi.org/10.1007/s10552-018-1058-4
Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, Rooyackers O, Zhou G, Williamson JM, Ljunqvist O, Efendic S, Moller DE, Thorell A, Goodyear LJ (2002) Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 51:2074–2081. https://doi.org/10.2337/diabetes.51.7.2074
Ng TP, Feng L, Yap KB, Lee TS, Tan CH, Winblad B (2014) Long-term metformin usage and cognitive function among older adults with diabetes. J Alzheimers Dis 41:61–68. https://doi.org/10.3233/JAD-131901
Palazon A, Tyrakis PA, Macias D, Velica P, Rundqvist H, Fitzpatrick S, Vojnovic N, Phan AT, Loman N, Hedenfalk I, Hatschek T, Lovrot J, Foukakis T, Goldrath AW, Bergh J, Johnson RS (2017) An HIF-1alpha/VEGF-A axis in cytotoxic T cells regulates tumor progression. Cancer Cell 32:669–683. https://doi.org/10.1016/j.ccell.2017.10.003
Piskovatska V, Stefanyshyn N, Storey KB, Vaiserman AM, Lushchak O (2019) Metformin as a geroprotector: experimental and clinical evidence. Biogerontology 20:33–48. https://doi.org/10.1007/s10522-018-9773-5
Podhorecka M, Ibanez B, Dmoszynska A (2017) Metformin - its potential anti-cancer and anti-aging effects. Postepy Hig Med Dosw (online) 71:170–175. https://doi.org/10.5604/01.3001.0010.3801
Pugliese G, Penno G, Natali A, Barutta F, Di Paolo S, Reboldi G, Gesualdo L, De Nicola L, Italian Diabetes S, The Italian Society Of N (2019) Diabetic kidney disease: new clinical and therapeutic issues. joint position statement of the italian diabetes society and the Italian society of nephrology on "the natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function. Nutr Metab Cardiovasc Dis 29:1127–1150. https://doi.org/10.1016/j.numecd.2019.07.017
Reitz KM, Marroquin OC, Zenati MS, Kennedy J, Korytkowski M, Tzeng E, Koscum S, Newhouse D, Garcia RM, Vates J, Billiar TR (2020) Association between preoperative metformin exposure and postoperative outcomes in adults with type 2 diabetes. JAMA Surg 155:e200416
Rezvanian H, Adibi N, Siavash M, Kachuei A, Shojaee-Moradie F, Asilian A (2009) Increased insulin sensitivity by metformin enhances intense-pulsed-light-assisted hair removal in patients with polycystic ovary syndrome. Dermatology 218:231–236. https://doi.org/10.1159/000187718
Rippe JM, Angelopoulos TJ (2016) Sugars, obesity, and cardiovascular disease: results from recent randomized control trials. Eur J Nutr 55:45–53. https://doi.org/10.1007/s00394-016-1257-2
Salani B, Maffioli S, Hamoudane M, Parodi A, Ravera S, Passalacqua M, Alama A, Nhiri M, Cordera R, Maggi D (2012) Caveolin-1 is essential for metformin inhibitory effect on IGF1 action in non-small-cell lung cancer cells. FASEB J 26:788–798. https://doi.org/10.1096/fj.11-192088
Saleh R, Nair VS, Murshed K, Nada MA, Elkord E, Shaheen R (2021) Correction to: transcriptome of CD8(+) tumor-infiltrating T cells: a link between diabetes and colorectal cancer. Cancer Immunol Immunother 70:2639–2640. https://doi.org/10.1007/s00262-021-02903-w
Samaras K, Makkar S, Crawford JD, Kochan NA, Wen W, Draper B, Trollor JN, Brodaty H, Sachdev PS (2020) Metformin use is associated with slowed cognitive decline and reduced incident dementia in older adults with Type 2 diabetes: the Sydney memory and ageing study. Diabetes Care 43:2691–2701
Sardu C, D’onofrio N, Torella M, Portoghese M, Mureddu S, Loreni F, Ferraraccio F, Panarese I, Trotta MC, Gatta G, Galdiero M, Sasso FC, D’amico M, De Feo M, Balestrieri ML, Paolisso G, Marfella R (2021) Metformin therapy effects on the expression of sodium-glucose cotransporter 2, leptin, and sirt6 levels in pericoronary fat excised from pre-diabetic patients with acute myocardial infarction. Biomedicines. https://doi.org/10.3390/biomedicines9080904
Sarmento-Cabral A, L-López F, Gahete MD, Castano JP, Luque RM (2017) Metformin reduces prostate tumor growth, in a diet-dependent manner, by modulating multiple signaling pathways. Mol Cancer Res 15:862–874. https://doi.org/10.1158/1541-7786.MCR-16-0493
Schernthaner G, Brand K, Bailey CJ (2022) Metformin and the heart: Update on mechanisms of cardiovascular protection with special reference to comorbid type 2 diabetes and heart failure. Metabolism 130:155160. https://doi.org/10.1016/j.metabol.2022.155160
Seneviratne A, Cave L, Hyde G, Moestrup SK, Carling D, Mason JC, Haskard DO, Boyle JJ (2021) Metformin directly suppresses atherosclerosis in normoglycaemic mice via haematopoietic adenosine monophosphate-activated protein kinase. Cardiovasc Res 117:1295–1308. https://doi.org/10.1093/cvr/cvaa171
Shi P, Liu W, Tala WH, Li F, Zhang H, Wu Y, Kong Y, Zhou Z, Wang C, Chen W, Liu R, Chen C (2017) Metformin suppresses triple-negative breast cancer stem cells by targeting KLF5 for degradation. Cell Discov 3:17010. https://doi.org/10.1038/celldisc.2017.10
Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72:7–33. https://doi.org/10.3322/caac.21708
Sigala DM, Hieronimus B, Medici V, Lee V, Nunez MV, Bremer AA, Cox CL, Price CA, Benyam Y, Chaudhari AJ, Abdelhafez Y, Mcgahan JP, Goran MI, Sirlin CB, Pacini G, Tura A, Keim NL, Havel PJ, Stanhope KL (2021) Consuming sucrose- or HFCS-sweetened beverages increases hepatic lipid and decreases insulin sensitivity in adults. J Clin Endocrinol Metab 106:3248–3264. https://doi.org/10.1210/clinem/dgab508
Snell-Bergeon JK (2017) Diabetes: Cardiovascular benefits of metformin in T1DM. Nat Rev Endocrinol 13:565–566. https://doi.org/10.1038/nrendo.2017.116
Soberanes S, Misharin AV, Jairaman A, Morales-Nebreda L, Mcquattie-Pimentel AC, Cho T, Hamanaka RB, Meliton AY, Reyfman PA, Walter JM, Chen CI, Chi M, Chiu S, Gonzalez-Gonzalez FJ, Antalek M, Abdala-Valencia H, Chiarella SE, Sun KA, Woods PS, Ghio AJ, Jain M, Perlman H, Ridge KM, Morimoto RI, Sznajder JI, Balch WE, Bhorade SM, Bharat A, Prakriya M, Chandel NS, Mutlu GM, Budinger GRS (2019) Metformin targets mitochondrial electron transport to reduce air-pollution-induced thrombosis. Cell Metab 29:335 e335-347. https://doi.org/10.1016/j.cmet.2018.09.019
Soliman GA, Shukla SK, Etekpo A, Gunda V, Steenson SM, Gautam N, Alnouti Y, Singh PK (2020) The synergistic effect of an ATP-competitive inhibitor of mtor and metformin on pancreatic tumor growth. Curr Dev Nutr 4:nzaa131. https://doi.org/10.1093/cdn/nzaa131
Stanhope KL (2016) Sugar consumption, metabolic disease and obesity: the state of the controversy. Crit Rev Clin Lab Sci 53:52–67. https://doi.org/10.3109/10408363.2015.1084990
Strekalova E, Malin D, Rajanala H, Cryns VL (2017) Metformin sensitizes triple-negative breast cancer to proapoptotic TRAIL receptor agonists by suppressing XIAP expression. Breast Cancer Res Treat 163:435–447. https://doi.org/10.1007/s10549-017-4201-0
Sun C, Hu SH, Dong BQ, Jiang S, Miao F, Lei TC (2021) Metformin promotes the hair-inductive activity of three-dimensional aggregates of epidermal and dermal cells self-assembled in vitro. Skin Pharmacol Physiol. https://doi.org/10.1159/000521400
Tariq N, Ayub R, Alam AY, Rahim F, Raees SR (2007) Clinical diagnosis of polycystic ovarian syndrome and response to metformin therapy. J Coll Physicians Surg Pak 17:469–472
Thanigaimani S, Singh TP, Unosson J, Phie J, Moxon J, Wanhainen A, Golledge J (2021) Editor’s Choice - association between metformin prescription and abdominal aortic aneurysm growth and clinical events: a systematic review and meta-analysis. Eur J Vasc Endovasc Surg 62:747–756. https://doi.org/10.1016/j.ejvs.2021.06.013
Thein D, Christiansen MN, Mogensen UM, Bundgaard JS, Rorth R, Madelaire C, Fosbol EL, Schou M, Torp-Pedersen C, Gislason G, Kober L, Kristensen SL (2020) Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study. Cardiovasc Diabetol 19:107. https://doi.org/10.1186/s12933-020-01078-5
Torres W, Nava M, Galbán N, Gómez Y, Morillo V, Rojas M, Cano C, Chacín M, DMarco L, Herazo Y, Velasco M, Bermúdez V, Rojas-Quintero J (2020) Anti-aging effect of metformin: a molecular and therapeutical perspective. Curr Pharm Des. https://doi.org/10.2174/1381612826666200716161610
Trinh SX, Nguyen HT, Saimuang K, Prachayasittikul V, Chan On W (2017) Metformin inhibits migration and invasion of cholangiocarcinoma cells. Asian Pac J Cancer Prev 18:473–477. https://doi.org/10.22034/APJCP.2017.18.2.473
Tseng CH (2021) Metformin use is associated with a lower risk of osteoporosis/vertebral fracture in Taiwanese patients with type 2 diabetes mellitus. Eur J Endocrinol 184:299–310
Van Bommel EJM, Ruiter D, Muskiet MHA, Van Baar MJB, Kramer MHH, Nieuwdorp M, Joles JA, Bjornstad P, Van Raalte DH (2020) Insulin sensitivity and renal hemodynamic function in metformin-treated adults with type 2 diabetes and preserved renal function. Diabetes Care 43:228–234. https://doi.org/10.2337/dc19-1651
Varghese S, Samuel SM, Varghese E, Kubatka P, Busselberg D (2019) High glucose represses the anti-proliferative and pro-apoptotic effect of metformin in triple negative breast cancer cells. Biomolecules. https://doi.org/10.3390/biom9010016
Wahdan-Alaswad RS, Cochrane DR, Spoelstra NS, Howe EN, Edgerton SM, Anderson SM, Thor AD, Richer JK (2014) Metformin-induced killing of triple-negative breast cancer cells is mediated by reduction in fatty acid synthase via miRNA-193b. Horm Cancer 5:374–389. https://doi.org/10.1007/s12672-014-0188-8
Wahdan-Alaswad R, Harrell JC, Fan Z, Edgerton SM, Liu B, Thor AD (2016) Metformin attenuates transforming growth factor beta (TGF-beta) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer. Cell Cycle 15:1046–1059. https://doi.org/10.1080/15384101.2016.1152432
Wang J, Gallagher D, Devito LM, Cancino GI, Tsui D, He L, Keller GM, Frankland PW, Kaplan DR, Miller FD (2012) Metformin activates an atypical PKC-CBP pathway to promote neurogenesis and enhance spatial memory formation. Cell Stem Cell 11:23–35. https://doi.org/10.1016/j.stem.2012.03.016
Wang L, Song Y, Wu GN, Yuan DM (2013) Association of the metformin with the risk of lung cancer: a meta-analysis. Transl Lung Cancer Res 2:259–263. https://doi.org/10.3978/j.issn.2218-6751.2013.08.01
Wang G, Dong Y, Liu H (2020a) Curcumol enhances the anti-tumor effects of metformin via suppressing epithelial-mesenchymal transition in triple-negative breast cancer. Ann Transl Med 8:946. https://doi.org/10.21037/atm-20-5438
Wang S, Lin Y, Xiong X, Wang L, Guo Y, Chen Y, Chen S, Wang G, Lin P, Chen H, Yeung SJ, Bremer E, Zhang H (2020b) Low-dose metformin reprograms the tumor immune microenvironment in human esophageal cancer: results of a phase II clinical trial. Clin Cancer Res 26:4921–4932. https://doi.org/10.1158/1078-0432.CCR-20-0113
Wen Q, Hu M, Lai M, Li J, Hu Z, Quan K, Liu J, Liu H, Meng Y, Wang S, Wen X, Yu C, Li S, Huang S, Zheng Y, Lin H, Liang X, Lu L, Mai Z, Zhang C, Wu T, Ng EHY, Stener-Victorin E, Ma H (2021) Effect of acupuncture and metformin on insulin sensitivity in women with polycystic ovary syndrome and insulin resistance: a three-armed randomized controlled trial. Hum Reprod. https://doi.org/10.1093/humrep/deab272
Westphal LP, Widmer R, Held U, Steigmiller K, Hametner C, Ringleb P, Curtze S, Martinez-Majander N, Tiainen M, Nolte CH, Scheitz JF, Erdur H, Polymeris AA, Traenka C, Eskandari A, Michel P, Heldner MR, Arnold M, Zini A, Vandelli L, Coutinho JM, Groot AE, Padjen V, Jovanovic DR, Bejot Y, Breniere C, Turc G, Seners P, Pezzini A, Magoni M, Leys D, Gilliot S, Scherrer MJ, Kagi G, Luft AR, Gensicke H, Nederkoorn P, Tatlisumak T, Engelter ST, Wegener S, Thrombolysis in Ischemic Stroke Patients Study G (2020) Association of prestroke metformin use, stroke severity, and thrombolysis outcome. Neurology 95:e362–e373. https://doi.org/10.1212/WNL.0000000000009951
Wu H, Esteve E, Tremaroli V, Khan MT, Caesar R, Mannerås-Holm L, Ståhlman M, Olsson LM, Serino M, Planas-Fèlix M, Xifra G (2017) Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med 23:850–858
Wu Y, Tu M, Huang Y, Liu Y, Zhang D (2020) Association of metformin with pregnancy outcomes in women with polycystic ovarian syndrome undergoing in vitro fertilization: a systematic review and meta-analysis. JAMA Netw Open 3:e2011995. https://doi.org/10.1001/jamanetworkopen.2020.11995
Xia W, Qi X, Li M, Wu Y, Sun L, Fan X, Yuan Y, Li J (2021) Metformin promotes anticancer activity of NK cells in a p38 MAPK dependent manner. Oncoimmunology 10:1995999. https://doi.org/10.1080/2162402X.2021.1995999
Xiao K, Liu F, Liu J, Xu J, Wu Q, Li X (2020) The effect of metformin on lung cancer risk and survival in patients with type 2 diabetes mellitus: a meta-analysis. J Clin Pharm Ther 45:783–792. https://doi.org/10.1111/jcpt.13167
Xie J, Xia L, Xiang W, He W, Yin H, Wang F, Gao T, Qi W, Yang Z, Yang X, Zhou T (2020) Metformin selectively inhibits metastatic colorectal cancer with the KRAS mutation by intracellular accumulation through silencing MATE1. Proc Natl Acad Sci USA 117:13012–13022
Xiong W, Sun KY, Zhu Y, Zhang X, Zhou YH, Zou X (2021) Metformin alleviates inflammation through suppressing FASN-dependent palmitoylation of Akt. Cell Death Dis 12:934. https://doi.org/10.1038/s41419-021-04235-0
Xu HY, Fang W, Huang ZW, Lu JC, Wang YQ, Tang QL, Song GH, Kang Y, Zhu XJ, Zou CY, Yang HL, Shen JN, Wang J (2017) Metformin reduces SATB2-mediated osteosarcoma stem cell-like phenotype and tumor growth via inhibition of N-cadherin/NF-kB signaling. Eur Rev Med Pharmacol Sci 21:4516–4528
Xu C, Li XF, Tian HY, Shi HJ, Zhang DD, Abasubong KP, Liu WB (2019) Metformin improves the glucose homeostasis of Wuchang bream fed high-carbohydrate diets: a dynamic study. Endocr Connect 8:182–194. https://doi.org/10.1530/EC-18-0517
Yang Z, Zhang X, Roberts RO, Roberts LR, Chaiteerakij R (2016) Metformin does not improve survival of cholangiocarcinoma patients with diabetes. Hepatology 63:667–668. https://doi.org/10.1002/hep.27821
Yuen N, Szulc-Lerch KU, Li YQ, Morshead CM, Mabbott DJ, Wong CS, Nieman BJ (2021) Metformin effects on brain development following cranial irradiation in a mouse model. Neuro Oncol 23:1523–1536. https://doi.org/10.1093/neuonc/noab131
Zaccardi F, Kloecker DE, Buse JB, Mathieu C, Khunti K, Davies MJ (2021) Use of metformin and cardiovascular effects of new classes of glucose-lowering agents: a meta-analysis of cardiovascular outcome trials in type 2 diabetes. Diabetes Care 44:e32–e34. https://doi.org/10.2337/dc20-2080
Zajda A, Huttunen KM, Sikora J, Podsiedlik M, Markowicz-Piasecka M (2020) Is metformin a geroprotector? A peek into the current clinical and experimental data. Mech Ageing Dev 191:111350. https://doi.org/10.1016/j.mad.2020.111350
Zang M, Zuccollo A, Hou X, Nagata D, Walsh K, Herscovitz H, Brecher P, Ruderman NB, Cohen RA (2004) AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J Biol Chem 279:47898–47905. https://doi.org/10.1074/jbc.M408149200
Zell JA, Mclaren CE, Morgan TR, Lawson MJ, Rezk S, Albers CG, Chen WP, Carmichael JC, Chung J, Richmond E, Rodriguez LM, Szabo E, Ford LG, Pollak MN, Meyskens FL (2020) A phase IIa trial of metformin for colorectal cancer risk reduction among individuals with history of colorectal adenomas and elevated body mass index. Cancer Prev Res (phila) 13:203–212. https://doi.org/10.1158/1940-6207.CAPR-18-0262
Zemdegs J, Martin H, Pintana H, Bullich S, Manta S, Marques MA, Moro C, Laye S, Ducrocq F, Chattipakorn N, Chattipakorn SC, Rampon C, Penicaud L, Fioramonti X, Guiard BP (2019) Metformin promotes anxiolytic and antidepressant-like responses in insulin-resistant mice by decreasing circulating branched-chain amino acids. J Neurosci 39:5935–5948. https://doi.org/10.1523/JNEUROSCI.2904-18.2019
Zemgulyte G, Tanaka S, Hide I, Sakai N, Pampuscenko K, Borutaite V, Rastenyte D (2021) Evaluation of the effectiveness of post-stroke metformin treatment using permanent middle cerebral artery occlusion in Rats. Pharmaceuticals (Basel). https://doi.org/10.3390/ph14040312
Zhang C, Ma S, Wu J, Luo L, Qiao S, Li R, Xu W, Wang N, Zhao B, Wang X, Zhang Y, Wang X (2020) A specific gut microbiota and metabolomic profiles shifts related to antidiabetic action: the similar and complementary antidiabetic properties of type 3 resistant starch from Canna edulis and metformin. Pharmacol Res 159:104985. https://doi.org/10.1016/j.phrs.2020.104985
Zhang Y, Liu C, Chen B, Chen F, Duan JY, Zhang MJ, Jiao J (2020b) Associations of impaired glucose metabolism with chronic peridontitis in pre-diabetes patients. Beijing Da Xue Xue Bao Yi Xue Ban 52:71–76
Zhu X, Shen J, Feng S, Huang C, Liu Z, Sun YE, Liu H (2020) Metformin improves cognition of aged mice by promoting cerebral angiogenesis and neurogenesis. Aging (Albany NY). https://doi.org/10.18632/aging.103693
Acknowledgements
This work was supported partly by The National Natural Science Foundation of China (81972366); The Natural Science Foundation of Guangdong (2022A1515012606); The Shenzhen Science and Technology Innovation Commission projects (JCYJ20220818101808018, KCXFZ202110203002406).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors confirm that there are no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Liu, J., Zhang, M., Deng, D. et al. The function, mechanisms, and clinical applications of metformin: potential drug, unlimited potentials. Arch. Pharm. Res. 46, 389–407 (2023). https://doi.org/10.1007/s12272-023-01445-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-023-01445-2